Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 1
2018 1
2019 1
2020 2
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.
Zacarías-Fluck MF, Massó-Vallés D, Giuntini F, González-Larreategui Í, Kaur J, Casacuberta-Serra S, Jauset T, Martínez-Martín S, Martín-Fernández G, Serrano Del Pozo E, Foradada L, Grueso J, Nonell L, Beaulieu ME, Whitfield JR, Soucek L. Zacarías-Fluck MF, et al. Among authors: masso valles d. Genes Dev. 2023 Apr 1;37(7-8):303-320. doi: 10.1101/gad.350078.122. Epub 2023 Apr 6. Genes Dev. 2023. PMID: 37024284 Free PMC article.
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.
Massó-Vallés D, Beaulieu ME, Jauset T, Giuntini F, Zacarías-Fluck MF, Foradada L, Martínez-Martín S, Serrano E, Martín-Fernández G, Casacuberta-Serra S, Castillo Cano V, Kaur J, López-Estévez S, Morcillo MÁ, Alzrigat M, Mahmoud L, Luque-García A, Escorihuela M, Guzman M, Arribas J, Serra V, Larsson LG, Whitfield JR, Soucek L. Massó-Vallés D, et al. Cancer Res Commun. 2022 Feb 21;2(2):110-130. doi: 10.1158/2767-9764.CRC-21-0103. eCollection 2022 Feb. Cancer Res Commun. 2022. PMID: 36860495 Free PMC article.
MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D, Beaulieu ME, Soucek L. Massó-Vallés D, et al. Expert Opin Ther Targets. 2020 Feb;24(2):101-114. doi: 10.1080/14728222.2020.1723548. Epub 2020 Feb 13. Expert Opin Ther Targets. 2020. PMID: 32003251 Review.
MYC targeting by OMO-103 in solid tumors: a phase 1 trial.
Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Martínez-Martín S, Foradada L, Alonso G, Massó-Vallés D, López-Estévez S, Jauset T, Corral de la Fuente E, Doger B, Hernández T, Perez-Lopez R, Arqués O, Castillo Cano V, Morales J, Whitfield JR, Niewel M, Soucek L, Calvo E. Garralda E, et al. Among authors: masso valles d. Nat Med. 2024 Mar;30(3):762-771. doi: 10.1038/s41591-024-02805-1. Epub 2024 Feb 6. Nat Med. 2024. PMID: 38321218 Free PMC article. Clinical Trial.
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets.
Zacarías-Fluck MF, Jauset T, Martínez-Martín S, Kaur J, Casacuberta-Serra S, Massó-Vallés D, Serrano Del Pozo E, Martín-Fernández G, González-Larreategui Í, López-Estévez S, Brown-Swigart L, Beaulieu ME, Whitfield JR, Madan B, Virshup DM, Evan GI, Soucek L. Zacarías-Fluck MF, et al. Among authors: masso valles d. Life Sci Alliance. 2021 Mar 2;4(5):e201900490. doi: 10.26508/lsa.201900490. Print 2021 May. Life Sci Alliance. 2021. PMID: 33653688 Free PMC article.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Beaulieu ME, et al. Among authors: masso valles d. Sci Transl Med. 2019 Mar 20;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012. Sci Transl Med. 2019. PMID: 30894502 Free PMC article.
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.
Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. Jauset T, et al. Among authors: masso valles d. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721157 Free PMC article.
Ibrutinib repurposing: from B-cell malignancies to solid tumors.
Massó-Vallés D, Jauset T, Soucek L. Massó-Vallés D, et al. Oncoscience. 2016 Jun 10;3(5-6):147-8. doi: 10.18632/oncoscience.310. eCollection 2016. Oncoscience. 2016. PMID: 27489860 Free PMC article. No abstract available.
13 results